Swertiamarin

CAS : 17388-39-5

Ref. 3D-MS10475

Informations sur le produit

• Nom: Swertiamarin
• Synonymes: (4aR,5R,6S)-5-Ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one, (4aR,5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside, (5R,6S)-5-ethenyl-4a-hydroxy-1-oxo-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-6-yl beta-D-glucopyranoside, 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR-(4aalpha,5beta,6alpha))-, 1H,3H-Pyrano(3,4-c)pyran-1-one, 5-ethenyl-6-(beta-d-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-, 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-, 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-<span class="text-smallcaps">D</span>-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-, Brn 0055278, Swertamarin, Swertiamarine, Swertiamaroside, Swertimarin, (4aR,5R,6S)-5-Ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-1H,3H-pyrano[3,4-c]pyran-1-one, 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, [4aR-(4aα,5β,6α)]-, 1H,3H-Pyrano[3,4-c]pyran-1-one, 5-ethenyl-6-(β-D-glucopyranosyloxy)-4,4a,5,6-tetrahydro-4a-hydroxy-, (4aR,5R,6S)-

Description

Swertiamarin is a natural compound that has been shown to have anti-steatotic activity in animal models. Swertiamarin was found to reduce the activity index for liver steatosis and increase the activity index for hepatic steatosis, which may be due to its ability to inhibit 5-hydroxytryptamine (5-HT)2 receptors. Swertiamarin also inhibits the activation of c-jun N-terminal kinase, which is a protein involved in cellular events such as apoptosis and inflammation. The molecular docking analysis of swertiamarin with the human 5-HT2A receptor showed that swertiamarin binds to the receptor with high affinity, inhibiting its function. The use of swertiamarin in combination with other natural compounds could be used as an alternative treatment for hepatic steatosis in humans.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 374.34 g/mol
• Formule: C₁₆H₂₂O₁₀
• Degré de pureté: Min. 98 Area-%
• Couleur/Forme: Powder